Recently, a three-person delegation from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", Hong Kong Stock Exchange code: 01541.HK) attended the 44th J.P. Morgan Healthcare Conference. Dr. Wenzhi Tian, Founder, Chairman, CEO, and CSO of the company, delivered a comprehensive corporate presentation at the Biotech Showcase™, introducing the company's development status and key program progress. Dr. Tian and the senior management team held intensive meetings with over ten multinational pharmaceutical and biotechnology companies during the conference, establishing in-depth communication with multiple potential partners post-event. Feedback has been positive, with substantive progress expected in 2026, injecting new momentum into the globalization of the company's pipeline.

The presentation materials from ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s Biotech Showcase™ corporate presentation are now available on the company's Investor Relations webpage at:https://cn.immuneonco.com/investor/promote/index.html#JInformation

2026 Outlook: Three Core Products Entering Pivotal Clinical Stages

The company anticipates multiple milestones in 2026, which will lay a solid foundation for subsequent international regulatory submissions:

IMM01

The Phase III study of IMM01 in CMML is expected to read out interim data as early as the fourth quarter. Targeting first-line CMML patients, enrollment is progressing smoothly, with 104 patients enrolled as of December 31, 2025. The company expects to complete enrollment of 132 patients by the end of March this year to support interim analysis, and plans to submit a preBLA application by the end of 2026. Its Phase Ib/II study in atherosclerosis will also advance to proof-of-concept stage.

IMM0306

The Phase III study of IMM0306 in R/R FL is expected to complete enrollment of the first patient in February.

IMM2510

The Phase II study of IMM2510 in combination with chemotherapy as neoadjuvant/adjuvant therapy for resectable squamous non-small cell lung cancer and esophageal cancer has been approved by the NMPA and is being initiated. The Phase II/III study of IMM2510 in endometrial cancer has also received NMPA approval, further expanding its application in solid tumors.